In the early trials, the vaccine showed efficacy in protection against influenza A, influenza B and COVID-19. Data also showed that the combination vaccine has a similar safety profile to Pfizer’s normal COVID-19 shot.
“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and healthcare systems all over the world,” said Annaliesa Anderson, PhD, senior vice president and the head of vaccine research and development at Pfizer.
The experimental shot will enter a phase 3 trial in a matter of months.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
